Categories: Business

J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion

Published by
TDG Syndication

Nov 16 (Reuters) – Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies. The drugmaker

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

TDG Syndication
Published by TDG Syndication